Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2007-09-11
2007-09-11
Harris, Alana M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S350000, C424S184100, C424S185100
Reexamination Certificate
active
09824787
ABSTRACT:
The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptides, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.
REFERENCES:
patent: 5856131 (1999-01-01), Hillman et al.
patent: 2002/0052308 (2002-05-01), Rosen et al.
patent: 2003/0166277 (2003-09-01), Zauderer et al.
patent: 2004/0063907 (2004-04-01), Zauderer et al.
patent: 2005/0042218 (2005-02-01), Zauderer
patent: 1 033 401 (2000-09-01), None
patent: WO99/33869 (1999-07-01), None
patent: WO99/37775 (1999-07-01), None
patent: WO 00/55173 (2000-09-01), None
patent: WO 00/55350 (2000-09-01), None
patent: WO 01/40269 (2001-06-01), None
patent: WO 01/74859 (2001-10-01), None
GenCore database, amino acid sequence comparison between Applicants' SEQ ID No. 2 and sequence 3 of U.S. Patent No. 5,856,131, Jan. 5, 1999.
Lazar et al. Molecular and Cellular Biology 8(3): 1247-1252, Mar. 1988.
GenCore database sheet (1). Amino acid alignment between Applicants' SEQ ID No. 2 and U.S. Patent application publication's sequence No. 966. May 2, 2002.
Lazar et. al. Molecular & Cellular Biology 8(3):1247-1252, Mar. 1988.
Lazar et al. Molecular and Cellular Biology 8(3): 1247-1252, Mar. 1988.
NCBI Entrez, GenBank Report, Accession No. H56704, from Hillier, L., et al., entry created 1995.
NCBI Entrez, GenBank Report, Accession No. H95363, from Hillier, L., et al., entry created 1995.
NCBI Entrez, GenBank Report, Accession No. H96055, from Hillier, L., et al., entry created 1995.
EMBL-EBI database, Accession No. AAG03153, Dumas Milne Edwards, J., et al., Entry date Oct. 6, 2000.
Del Val, M., et al., “Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on Its Neighboring Residues in the Protein,”Cell66:1145-1153, Cell Press (1991).
Eisenlohr, L.C., et al., “Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes,”J. Exp. Med.175:481-487, Rockefeller University Press (1992).
Yewdell, J. W., and Bennink, J.R., “Cell Biology of Antigen Processing and Presentation to Major Histocompatibility Complex Class I Molecule-Restricted T Lymphocytes,”Adv. Immunol.52:1-123, Academic Press, Inc. (1992).
Borrello Melinda A.
Evans Elizabeth E.
Zauderer Maurice
Harris Alana M.
University of Rochester
LandOfFree
Gene differentially expressed in breast and bladder cancer,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene differentially expressed in breast and bladder cancer,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene differentially expressed in breast and bladder cancer,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3748920